-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – rosuvastatin ER
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry rosuvastatin ER Drug Details Rosuvastatin extended-release capsule (LYN-047) is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (atorvastatin + ezetimibe)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (atorvastatin + ezetimibe) Drug Details Atorvastation in combination with ezetimibe is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (ezetimibe + rosuvastatin + telmisartan)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (ezetimibe + rosuvastatin + telmisartan) Drug Details NVP-1805 is under development for the treatment...
-
Product Insights
Net Present Value Model: Colesevelam Hydrochloride
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Colesevelam Hydrochloride Drug Details Colesevelam hydrochloride...
-
Product Insights
Net Present Value Model: Zetia
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Zetia Drug Details Ezetimibe (Zetia/ Ezetrol/...
-
Product Insights
Net Present Value Model: Repatha
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Repatha Drug Details Evolocumab (AMG-145, Repatha)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ecostatin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ecostatin Drug Details Ecostatin is under development for the treatment of hyperlipidemia. The drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (amlodipine maleate + rosuvastatin calcium + telmisartan)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (amlodipine maleate + rosuvastatin calcium + telmisartan) Drug Details DW-1501 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – atorvastatin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry atorvastatin Drug Details Atorvastatin is under development for the treatment of hypercholesterolemia. It is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (metformin hydrochloride + rosuvastatin calcium)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry (metformin hydrochloride + rosuvastatin calcium) Drug Details JLP-1310 (fixed dose combination of metformin hydrochloride...